Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report
Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pathway, ritonavir can potentially cause serious dru...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sultan Qaboos University
2017-08-01
|
Series: | Sultan Qaboos University Medical Journal |
Subjects: | |
Online Access: | https://journals.squ.edu.om/index.php/squmj/article/view/2234 |
id |
doaj-7c0b7626d5294daa903befbe40c24fa2 |
---|---|
record_format |
Article |
spelling |
doaj-7c0b7626d5294daa903befbe40c24fa22020-11-25T02:53:10ZengSultan Qaboos UniversitySultan Qaboos University Medical Journal 2075-051X2075-05282017-08-0117333934210.18295/squmj.2017.17.03.0142154Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case reportAli Al-Maqbali0Bina Kamble1Salim Al-Qassabi2Ali Elgalib3Department of Communicable Disease Surveillance & Control, Directorate General of Health Services, Ministry of Health, Al Batinah North Governorate, OmanDepartment of Internal Medicine, Al-Nahdha Hospital, Muscat, OmanDepartment of Internal Medicine, Al-Nahdha Hospital, Muscat, OmanDepartment of Internal Medicine, Al-Nahdha Hospital, Muscat, OmanRitonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pathway, ritonavir can potentially cause serious drug-drug interactions. Inhaled fluticasone propionate, which is used to treat asthma and chronic obstructive airway disease, is particularly prone to such interactions due to its physiological attributes. We report a HIV-positive 48-year-old male patient who presented to Al Nahdha Hospital, Muscat, Oman, in 2012 with weight loss, generalised weakness and fatigue and diagnosed with secondary adrenal insufficiency as a result of concomitant ritonavir and inhaled fluticasone.https://journals.squ.edu.om/index.php/squmj/article/view/2234human immunodeficiency virusritonavirfluticasonedrug interactionsadrenal insufficiencycase reportoman. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ali Al-Maqbali Bina Kamble Salim Al-Qassabi Ali Elgalib |
spellingShingle |
Ali Al-Maqbali Bina Kamble Salim Al-Qassabi Ali Elgalib Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report Sultan Qaboos University Medical Journal human immunodeficiency virus ritonavir fluticasone drug interactions adrenal insufficiency case report oman. |
author_facet |
Ali Al-Maqbali Bina Kamble Salim Al-Qassabi Ali Elgalib |
author_sort |
Ali Al-Maqbali |
title |
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report |
title_short |
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report |
title_full |
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report |
title_fullStr |
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report |
title_full_unstemmed |
Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate : Case report |
title_sort |
secondary adrenal insufficiency due to the co-administration of ritonavir and inhaled fluticasone propionate : case report |
publisher |
Sultan Qaboos University |
series |
Sultan Qaboos University Medical Journal |
issn |
2075-051X 2075-0528 |
publishDate |
2017-08-01 |
description |
Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other drugs that are metabolised via the CYP3A4 pathway, ritonavir can potentially cause serious drug-drug interactions. Inhaled fluticasone propionate, which is used to treat asthma and chronic obstructive airway disease, is particularly prone to such interactions due to its physiological attributes. We report a HIV-positive 48-year-old male patient who presented to Al Nahdha Hospital, Muscat, Oman, in 2012 with weight loss, generalised weakness and fatigue and diagnosed with secondary adrenal insufficiency as a result of concomitant ritonavir and inhaled fluticasone. |
topic |
human immunodeficiency virus ritonavir fluticasone drug interactions adrenal insufficiency case report oman. |
url |
https://journals.squ.edu.om/index.php/squmj/article/view/2234 |
work_keys_str_mv |
AT alialmaqbali secondaryadrenalinsufficiencyduetothecoadministrationofritonavirandinhaledfluticasonepropionatecasereport AT binakamble secondaryadrenalinsufficiencyduetothecoadministrationofritonavirandinhaledfluticasonepropionatecasereport AT salimalqassabi secondaryadrenalinsufficiencyduetothecoadministrationofritonavirandinhaledfluticasonepropionatecasereport AT alielgalib secondaryadrenalinsufficiencyduetothecoadministrationofritonavirandinhaledfluticasonepropionatecasereport |
_version_ |
1724726311284375552 |